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Objective: To describe the change in the mean hepatic apparent diffusion coefficient (ADC) 
and hepatic fat fraction (HFF) during body weight (BW) gain in cats using MRI.  
Animals: Twelve healthy adult male cats. 
Procedures: The cats underwent MRI examination. Sequences included multiple echo GRE 
MRI, and diffusion-weighted MRI (DW-MRI) (b-values: 0, 400, 800 s/mm2) at time point 0. 
After 40 weeks of being fed with high energy food ad libitum, the cats underwent a second 
MRI examination (time point 1). In different regions of interest (ROIs) in the liver 
parenchyma, BW, HFF, and the ADC were recorded at the two time points. 
Results: At time point 0 and 1, respectively, the median BW was 4.5 kg (range, 3.6–5.3 kg) 
and 6.5 kg (range, 4.3–8.7 kg); the mean HFF was 3.39 ± 0.89% and 5.37 ± 1.92%; the mean 
hepatic ADC was 1.21 ± 0.08 × 10−3 mm2/s and 1.01 ± 0.2 × 10−3 mm2/s. Statistically 
significant differences between the two time points were found for BW, HFF, and the ADC. 
The HFF was positively associated with the BW, the ADC was negatively associated with 
HFF. 
Conclusions and clinical relevance: The hepatic ADC depends on factors related to the 
patient. Similar to humans, cats exhibit decreased hepatic ADC with increased HFF. Protons 
associated with fat tissue may reduce diffusivity, resulting in a lower ADC than in liver with 
lower HFF. Additional studies in cats with different nutritional states and over longer periods 








Zielsetzung: Beschreibung der Veränderung des mittleren scheinbaren 
Diffusionskoeffizienten (ADC) und der Leberfettfraktion (HFF) bei Katzen während der 
Gewichtszunahme mittels MRT. 
Tiere: Zwölf gesunde männliche erwachsene Katzen. 
Durchführung: Zwei MRI Untersuchungen, mit multiple echo GRE MRI und diffusion-
weighted MRI (DW-MRI) Sequenzen, wurden durchgeführt. 40 Wochen nach Fütterung einer 
hochenergetischen Nahrung ad libitum erfolgte die zweite Untersuchung. 
Das Körpergewicht (KG) sowie die HFF und der ADC in verschiedenen ROIs des 
Leberparenchyms wurden gemessen.  
Resultate: Der Median des KG der ersten Messung lag bei 4.5 kg (3.6 – 5.3 kg) und der 
zweiten bei 6.5 kg (4.3 – 8.7 kg). Der Mittelwert der HFF lag bei der ersten Messung bei 3.39 
± 0.89% und bei der zweiten bei 5.37 ± 1.92%. Der Mittelwert des ADC lag bei der ersten 
Messung bei 1.21 ± 0.08 × 10−3 mm2/s, bei der zweiten bei 1.01 ± 0.2 × 10−3 mm2/s. 
Statistisch signifikante Unterschiede zwischen den zwei Zeitpunkten wurden für das KG, die 
HFF und den ADC gefunden. Die HFF ist positiv assoziiert mit dem KG und der ADC 
negativ mit der HFF. 
Zusammenfassung und klinische Relevanz: Der ADC hängt von patientenbezogenen 
Faktoren ab. Wie beim Menschen gezeigt werden konnte, führt eine Erhöhung der HFF zu 
einer Senkung des hepatischen ADC. Mit Fettgewebe assoziierte Protonen könnten die 
Diffusionsfähigkeit verringern, was bei hoher HFF zu einem niedrigeren ADC führt als bei 
Lebergewebe mit niedriger HFF. 
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ADC   Apparent diffusion coefficient 
BW   Body weight 
DW-MRI  Diffusion-weighted MRI 
FHL    Feline hepatic lipidosis 
HFF    Hepatic fat fraction 
GRE   Gradient recalled echo 
PDFF   Proton density fat fraction 
ROI   Region of interest 
T0   Initial time point zero 




DW-MRI is a functional imaging method that allows a qualitative and quantitative 
assessment of liver tissue diffusivity.  Historically, the use of DW-MRI has been described for 
brain investigations1-4, but an emerging application of DW-MRI in veterinary medicine is the 
examination of abdominal organs. 
In human medicine, DWI-MRI is used in routine MRI examination of the liver and 
enables the detection of focal lesions and diffuse hepatic diseases.5 The ADC is derived from 
DWI-MRI images and represents the quantification of the random motion of water molecules 
in biological tissues. It has been shown to be an adequate method for predicting liver fibrosis 
and inflammation and is used to help differentiate between benign and malignant focal 
lesions.6 The ADC is, though, dependent on patients characteristics, among others, the HFF. 
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The association of reduced ADC with higher HFF has been reported in humans, as well as in 
a murine model.5,7-9 Other studies could not find a correlation between HFF and the ADC.10 
Hepatic fat accumulation with consequent increased HFF occurs in domestic cats 
secondary to obesity, 11 and pathological conditions as diabetes, 12 and FHL.13 Overweight 
and obesity are increasing problems in cats, 14 and FHL is the most common hepatobiliary 
disorder in adult cats. 13,15 Obesity and FHL are also correlated processes: obese cats have a 
significant higher liver fat concentration than lean cats, 16 so those that are overweight and 
obese are at risk for the development of FHL. Increased HFF is clinically difficult to quantify, 
and its clinical significance may be variable. Noninvasive techniques to evaluate hepatic fat 
content in clinical practice are usually limited to ultrasound and computer tomography, but 
both modalities lack specificity and allow only semiquantitative evaluation of fat content.17 
Assessment of hepatic steatosis for clinical care requires not only diagnosis but also grading 
of severity. 
 In human medicine, hepatic steatosis is a pathogenic, potentially reversible condition 
and there is an urgent need, in both clinical and research arenas to detect its presence and to 
assess its severity.18 The same needs are shared by veterinary medicine. 
A substantial number of studies, mostly in humans, demonstrated that MRI allows a 
noninvasive, accurate, reproduceable, precise, and reader-independent quantification of HFF 
regardless of the degree of hepatic lipidosis.19,20,17,21-26 One recently commercially released 
multiple echo GRE pulse sequence enables accurate and consistent measurement of HFF.27 
To the authors’ knowledge, no study has investigated the correlation of the hepatic 
ADC and HFF in cats. The purpose of the present study was to investigate the effect of 
increasing HFF on the ADC of the feline liver during BW gain in healthy cats. This effect 
could affect the interpretation of DW-MRI on hepatic parenchyma. 
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Materials and Methods 
The present prospective sample survey study was approved by the Cantonal 
Veterinary Office of Zurich (license number, ZH118-16) in accordance with the Animal 
Welfare Act of Switzerland and as a part of a main concurrent study. 
The cats underwent two MRI examinations at the initial time point (T0) and 40 weeks 
later at time point 1 (T1). 
Animals 
Twelve neutered male adult research purpose-bred shorthair cats were enrolled in this 
study. At T0, all cats underwent a clinical examination. Based on a physical examination, 
hematological and biochemical tests, all cats were deemed to be in good health, except two 
cats with mild elevated renal values (chronic kidney disease stage 2 according to International 
Renal Interest Society guidelines). Ten cats were classified as American Society of 
Anesthesiologists I; the two cats with elevated renal values were classified as American 
Society of Anesthesiologists II.  
At T1, the physical examination, hematological and biochemical tests were repeated in 
all cats. Ten cats were confirmed classified as American Society of Anesthesiologists I; the 
two cats classified as American Society of Anesthesiologists II were excluded from the 
second examination due to causes that are not related to the study. 
The BW of the cats was recorded before each MRI examination. After the initial MRI 
examination, the cats were fed a commercial dry fooda ad libitum for 16 weeks or until they 
were overweight (body condition score, 7/9). Subsequently, the amount of food was adjusted 
to maintain this BW. 
Anesthesia 
The cats were fasted for 12 h before anesthesia. Premedication consisted of ketamine 
(10 mg/kg), midazolam (0.1 mg/kg), and butorphanol (0.3 mg/kg) intramuscularly. After 
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premedication, a catheter was aseptically placed in the left or right cephalic vein for 
administration of contrast medium, IV medication, and lactated Ringer’s solution (3 
mL/kg/h). 
Oxygen was administered via a facemask for 30 min prior to anesthesia induction.  
Anesthesia was induced with alfaxalone (0.5–2 mg/kg) intravenously. After induction, the 
cats were intubated with a cuffed endotracheal tube and mechanically ventilated with positive 
end-expiratory pressure in a pressure-controlled mode (5–11 cm H2O). The respiratory rate 
was adjusted to achieve an end-tidal CO2 of 35–42 mmHg (4.66–5.59 kPa). 
The anesthesia was maintained using isoflurane with a 1:1 ratio of oxygen and air.  
Anesthesia was monitored and recorded with a multiparameter monitor that included 
spirometry, capnography, and an MRI-compatible wireless respiratory sensor, as well as 
vectorcardiography and pulse oximetry. 
Glycopyrrolate (10 mcg/kg, IV) was administered if the pulse rate fell below 100 bpm 
for longer than 10 min. If necessary, this procedure was repeated once. 
MRI 
All cats were placed in dorsal recumbency in a 3 Telsa MRI scannerb with a phased-
array anterior coil.c MRI examination included morphological images to exclude liver 
abnormalities. Performed sequences were as follows: T2-weighted (turbo spin echo; repetition 
time/echo time, 2,000/80 ms; flip angle, 90°; field of view, adapted to animal; voxel size, 
1.18/1.42/3.00 mm; slice thickness, 3 mm; slice gap, 0 mm) and T1-weighted precontrast 
sequence (mDixon, gradient echo; repetition time/echo time 1/echo time 2, 3.7/1.21/2.4 ms; 
flip angle, 10°; field of view, adapted to animal; voxel size, 1.5/1.5/3.00 mm; slice thickness, 
3 mm; slice gap, ˗1.5 mm). 
For the fat quantification, a multiple echo GRE (multi-echo acquisition, multi-peak 
mDIXON sequence with T2* correction)d was performed. The following sequence parameters 
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were used: breath hold, expiration; repetition time/echo time 1/delta echo time, 7.5/1.23/1.0 
ms; flip angle, 3°; field of view, adapted to animal; slice thickness, 4 mm; slice gap, ˗2 mm; 
acquired voxel size, 1.5/1.49/4 mm; echoes, 6. The breath hold technique was used for a 
maximum of 21.3 s. Therefore, controlled mechanical ventilation was discontinued to force 
brief expiratory apnea and was continued immediately after the sequence. 
DWI-MRI was performed (3b imaging performance sensitivity encoding) with the 
following parameters: repetition time/echo time, 1.8 s/75 ms; flip angle, 90°; field of view, 
adapted to animal; slice thickness, 4 mm; slice gap, 0.4 mm; acquired voxel size, 1.96/1.83/4 
mm; number of b-values, 3 (0, 400, 800  s/mm2). 
The following T1-weighted postcontrast sequence was performed after hand injection 
of contrast mediume (0.3 mL/kg, IV), followed by a 10 mL saline (0.9% NaCl) solution: 
mDixon, gradient echo; repetition time/echo time 1/echo time 2, 3.7/1.21/2.4 ms; flip angle, 
10°; field of view, adapted to animal; voxel size, 1.5/1.5/3.00 mm; slice thickness, 3 mm; 
slice gap, ˗1.5 mm). 
All images were acquired in the transverse plane. 
Postprocessing and data analysis 
Postprocessing of the multiple echo GRE sequence was performed on the workstation 
of the previously described MRI unit, and DW-MRI was performed on a dedicated extended 
workstation.f 
HFF was evaluated qualitatively and quantitatively. The qualitative evaluation was 
performed using a color-coded map. Tissue with no fat content is displayed in dark violet. 
Progressively increasing fat component is displayed as gradually brighter colors (from violet 
to blue, green, yellow, and orange). Fat component of approximately 80% to pure fat tissue is 
displayed in red. For the quantitative evaluation of HFF, 4 ROIs of similar size were manually 
drawn on the liver parenchyma using an adjustable round cursor on the automatically 
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generated fat fraction images. The ROIs were drawn in the right cranial, right caudal, middle, 
and left liver parenchyma. Based on the DW-MRI, the software automatically generated a 
ADC map. Three ROIs of similar size were manually drawn on the liver parenchyma using an 
adjustable round cursor on the ADC map. The ROIs were drawn in the middle right, middle 
left, and cranial liver parenchyma in areas with subjectively homogeneous signal intensity as 
otherwise described.28  In all cases, care was taken to avoiding major blood vessels, the 
gallbladder, and obvious image artifacts. 
Statistical analysis 
Statistical analyses were performed using a free software environment for statistical 
computing.g Descriptive statistics were calculated, and numerical data were reported as the 
mean ± SD, median and range, or numbers (%) where appropriate. 
Normal distribution was tested using the Shapiro-Wilk test, and significant differences 
in paired data were determined using the Wilcoxon test. The relationship between the ADC 
and HFF was analyzed using a generalized mixed effect model. The relationship between the 
BW and HFF was also analyzed using a generalized mixed effect model. 
P-values were considered to be significant when less than 0.05. 
 
Results 
Twelve cats were evaluated at T0; at T1, 10 were evaluated. The median age at the 
beginning of the study was 77 months (range, 75–78 months). The physical examination, 
hematological and biochemical tests of hepatic panel were unremarkable in all cats at T0 and 
T1. At T0, median BW was 4.52 kg (range, 3.6–5.3 kg) and a T1 was 6.35 kg (range, 4.3–8.7 
kg). This difference in BW was statistically significant between the two time points (p < 
0.001). 
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The mean acquisition time was 99.76 ± 12.65 s for the T2-weighted sequence; 10.85 ± 
2.75 s for T1-weighted precontrast; 9.27 ± 2.37 s for T1-weighted postcontrast; 3 min 28 s ± 
47 s for diffusion-weighted imaging; and 14.3 ± 1.7 s for the multiple echo GRE sequence. 
The morphological images of all feline livers were considered unremarkable in T2- 
and T1-weighted precontrast and postcontrast sequences at both time points. All livers were 
homogeneous hyperintense to the epaxial musculature and hypointense to the spleen on T2-
weighted images, homogeneously and mildly hyperintense to epaxial muscles and spleen on 
precontrast T1-weighted images, and homogenously hyperintense to epaxial muscles and 
spleen and on postcontrast T1-weighted images. 
Regarding the qualitative assessment of the livers using the color-coded map of the 
multiple echo GRE sequence at T0, the livers of 3 cats were almost completely dark violet 
with only traces of bright violet. The dark violet component was subjectively more extensive 
than the bright violet component in the other 9 cats. At T1, the livers of 3 cats exhibited dark 
and bright violet components with subjectively equal distribution. In the other 7 cats, the 
bright violet component was subjectively more extensive than the dark violet component. No 
cases showed visible blue areas (Figure 1). 
The mean HFF was 3.39 ± 0.89% at T0 and 5.37 ± 1.92% at T1, with a statistically 
significant difference between the two time points (p = 0.005) (Figure 2). The mean hepatic 
ADC was 1.21 ± 0.08 × 10−3 mm2/s at T0 and 1.01 ± 0.2 × 10−3 mm2/s at T1, with a 
statistically significant difference between the two time points (p = 0.037) (Figure 3). The 
changes and the relationship between BW, HFF, and ADC at T0 and T1 is shown in Figure 4.  
The mean ROI size for HFF measurements was 95.6 ± 3.1 mm2 (96.6 ± 3.4 mm2 at T0 
and 94.6 ± 3.8 mm2. at T1), with no statistically significant difference between the two time 
points (p = 0.114). The median size of the ROI on the ADC map was 51.4 ± 9.2 mm2 (50.1 ± 
12.0 mm2 
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at T0 and 52.8 ± 4.9 mm2 at T1), with no statistically significant difference between the two 
time points (p = 0.314). 
The generalized mixed effect models suggested that the hepatic ADC was negatively 
associated with BW (p < 0.001), as well as negatively associated with HFF measured using 
the multiple echo GRE sequence (p < 0.001). The model predicts a 0.29% reduction in the 




Our study showed that one of the factors influencing the hepatic ADC in cats is HFF. An 
increase in HFF measured with the multiple echo GRE sequence following BW gain is 
associated with significantly reduced ADC. As conditions related to increased HFF in cats are 
common, this association must be considered when DW-MRI of the liver is performed to 
avoid misinterpretation. MRI is increasingly used in veterinary medicine to assess liver 
disease due to its potential diagnostic value. So far, DW-MRI of the feline liver has only been 
reported in a small group of healthy cats.28 
In human medicine, studies have shown that determining the ADC is a useful imaging 
method to help differentiate benign and malignant liver lesions to predict the severity of 
hepatic fibrosis and monitor the progress of treatment response.6,29-32 The ADC is a common 
index derived from DW-MRI sequences and quantifies the diffusion of water molecules 
within biological tissue.33 The sensitivity of the imaging sequence to water diffusion can be 
altered by determine the b-value. In the present study, the b-values of 0, 400, and 800 s/mm2 
were chosen to obtain images with an acceptable spatial resolution, and considering the 
current literature. Three b-values were used to deliver a more accurate calculation of the 
ADC.33,34 
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However, in a clinical setting, comparing the hepatic ADC between patients should be 
exercised with caution because the value depends on many technical factors and factors 
related to the patient. Technical factors that can influence the ADC are field strength, imaging 
platform, applied gradients strength and magnitude (b-values), coils, different manufactures, 
software, acquisition parameters, and other factors.35-37 In the present study, these bias factors 
were minimized because the two examinations included the same equipment and sequence 
parameters. Factors related to the patient that can influence the ADC include patient age38, 
motion from neighboring organs39, and pathological processes such as hepatic steatosis.40 
Being the same cats evaluated twice, also variation of factors related to the patients have been 
minimized, and is reasonable to assume that the change in ADC truly depends on the HFF and 
BW gain, the only factors that significantly changed between the 2 time points.   
Regarding technical considerations, we used in the present study, a free-breathing 
technique due to the shorter acquisition time and the impossibilities of a triggered sequence in 
cats, considering the shallow respiration movements. In addition, the free-breathing method is 
recommended in humans.41  
DW-MRI sequences in abdominal studies are still not routinely used in veterinary 
medicine. Despite equipment requirements and high costs, this technique is promising as non 
invasive diagnostic tool in hepatic diseases. The technical advantages of DW-MRI include the 
following: brief scanning times due to new technologies (mean of 3 min 28 s), which makes 
its use in standard protocols for clinical examinations possible, and the avoidance of 
exogenous contrast agent. The major technical disadvantages of DW-MRI are the limited 
spatial resolution, sensitivity to artifacts, and need for general anesthesia. Literature on DW-
MRI applied to liver examination is still lacking in feline medicine, with no studies 
documenting variability of ADC.  
 17 
Liver biopsy is currently accepted as the gold standard for determining increased liver 
fat content and FHL23. Liver biopsy has important limitations: it is an invasive technique that 
can cause pain, transient hypotension, and other complications such as bleeding, infections, 
bile leakage, pneumothorax, and hemothorax.42,43 Furthermore, it is not a suitable technique 
for follow up. Hepatic fat accumulation can be heterogeneously distributed across the liver, so 
a biopsy sample may not be representative of the pathological processes and lead to a non 
accurate estimation of hepatic fat.43,44 Clinically, the severity of FHL is histologically 
assessed by estimating the percentage of hepatocytes containing fat droplets. Thus, 
interpretation of the biopsy is subjective and semiquantitative.45As a result, alternative 
methods for screening and monitoring increased HFF and FHL, and clinical decision-making 
are needed.23,43,44,46 
The multiple echo GRE sequence allows PDFF measurements for the estimation of 
HFF due to a pixel-by-pixel reconstruction algorithm-based separation between water and fat 
and creates a water-only, fat-only, in-phase, opposed-phase, fat fraction and T2* images. In 
humans, PDFF measurements have been determined to be a reliable and reproducible 
estimation of HFF across different manufacturers and field strengths.27 Sequences based on 
multiple echo GRE techniques with fat-water separation, yield quantification of the HFF 
highly correlated with the estimation of HFF validated mean other invasive and noninvasive 
techniques.47,48 49,50  
This correlation has been described between values obtained by PDFF and HFF values 
obtained mean MRI-spectroscopy and histology (among others51). In particular, the 
correlation between HFF measured with PDFF techniques and other invasive or noninvasive 
techniques has been reported in dogs24, geese52, and mice.53 
The primary advantages of the described multiple echo GRE sequence are that it 
allows visualization and then assessment of the entire liver parenchyma and that images are 
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produced in a single breath hold. The lack of ionizing radiation, the short time of 
investigation, and the repeatability of the results make the described multiple echo GRE 
sequence a suitable tool for monitoring disease and evaluating therapy efficacy. Beside the 
quantitative analysis of the HFF mean drawing of ROIs, a color-coded map can be created. 
That allows visually display of the amount of fat in the liver, and enables convenient 
comparison of images acquired at T0 and T1 in the same regions, or comparison between 
multiple echo GRE images and other sequences. In the analyzed cats, increased HFF was 
apparent even on images comparison only. The distribution of the different colors reflects the 
uniformity of fat accumulation in the present study.  That could represent an important 
clinical application of the technique, mainly in cats with higher HFF than the population of 
the present study.  
For a more precise quantification of the HFF, multiple ROIs have been drawn on the 
hepatic parenchyma. The choice of the number, location and size of the ROIs was based on 
the available literature on human medicine 54 and on healthy dogs.24  
In human medicine, a negative correlation similar to our data between HFF and ADC has 
been found.5,7,9 The current hypothesis is that fat droplets inside hepatocytes and extracellular 
fat accumulation impedes the movement of water, resulting in a reduction in the ADC. 5 It is 
likely that, similarly to what is described in human medicine, also in the examined cats, 
protons associated with intra- and extracellular fat reduce the interstitial space and reduce 
diffusivity. 
 Inflammation and fibrosis may be additional causes for a reduction in the ADC, as 
other studies postulated in human medicine. 5 In the present study, concurrent diseases were 
considered unlikely, based on the normal morphological images and the lack of biochemical 
abnormalities in the hepatic panel at both time points. 
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The two primary limitations of the present study were its small sample size and 
limited observation period, both due to animal welfare reasons. The positive association 
between BW gain and HFF is expected. Our data show that the HFF increases, during BW 
gain, in a relatively short period of time. The maximum mean HFF in the cats of our study 
was 5.37%. In human medicine, hepatic lipidosis is defined by a PDFF greater than 5.6% 
assessed by quantitative fat-water separation MRI in adult patients 55 and greater than 5% in 
children.56 No corresponding data are available in feline medicine, but taking these data as 
reference, the HFF of the analyzed cats are at the cut off values of the definition of FHL. 
These cats, though, were defined as healthy, so it is possible the increased HFF could indicate 
an early and pre-clinical stage of FHL. 
Moreover, PDFF and hepatic triglyceride content was not biochemically confirmed 
from liver biopsies. A histological examination of the liver parenchyma would have not 
provided quantification of HFF but may have excluded concurrent diseases at the histological 
level. 
Due to the different spatial resolutions of the DW-MRI and multiple echo GRE 
images, it was not possible to draw the ROIs exactly in the same localization of the hepatic 
parenchyma. Thus, some degree of spatial mismatch between the locations of the two 
measurements must be taken into account. In this study, the increase in HFF was limited and 
achieved in a relatively short period of time. Further studies conducted over a longer period in 
cats with a higher body condition score and higher HFF, as well in animals with FHL, are 
needed to completely understand the correlation between the ADC, HFF and BW. We would 
expect an even more marked correlation between the ADC and HFF during longer 
observation periods. 
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 Our study suggests that the hepatic ADC is negatively associated with the HFF 
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Figure 1. Colored map derived from the multiple echo GRE sequence in transverse view of 
one cat of the study at T0 (A, 77 months old, 4.1 kg BW) and T1(B, 40 weeks later, 5.6 kg 
BW). At T0, the liver was predominantly dark violet. At T1, the liver was predominantly 
bright violet. Increased subcutaneous and visceral fat tissue is visible at T1. Color scala on the 
right of the image. Dorsal on the top of the images and right side on the left of the images. 
Scale bar = 1 cm. 
 
Figure 2. Transverse multiple echo GRE sequence of one cat of the study at T0 (A, 75 
months old, 4.6 kg BW) and T1(B, 40 weeks later, 5.8 kg BW). Optically, no difference of the 
signal intensity of the liver is visible. Estimated HFF in the ROI (white circle in the right 
 28 
hepatic parenchyma) was 3.3% at T0 and 4.18% at T1. Increased subcutaneous and visceral 
fat tissue is visible at T1. Dorsal on the top of the image and right side on the left of the 
image. 
Scale bar = 1 cm. 
 
Figure 3. ADC map in transverse view of the liver of one cat of the study at T0 (A, 75 
months old, 4.7 kg BW, HFF 3.13%) and T1 (B, 40 weeks later, 6.5 kg BW, HFF 4.12%). 
Optically, no difference of the signal intensity of the ADC map is visible. Measured ADC on 
the ROI (white circle in the right liver parenchyma) was 1.19 × 10−3 mm2/s at T0 and 0.9 × 
10−3 mm2/s at T1. The limited spatial resolution is visible. Dorsal on the top of the image and 




Figure 4: Box plots of the mean BW, HFF, and ADC at T0 and T1. BW_T0 and BW_T1 
expressed in kg; HFF_T0 and HFF_T1 expressed in %; ADC_T0 and ADC_T1 expressed in 
unit × 10−3 mm2/s.  
For each plot, the box represents the 25th to 75th percentiles, and the dark line represents the 
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